Exenatide vs Liraglutide
Exenatide (GLP-1 receptor agonist) and Liraglutide (GLP-1 receptor agonist) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Page updated 2026-09-20. Latest review of a source entry: 2026-09-20. Editorial method.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Exenatide | Liraglutide |
|---|---|---|
| Compound class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Research category | GLP-1 Family | GLP-1 Family |
| Length (amino acids) | Not documented | 31 amino acids |
| Molecular weight | Not documented | 3751.2 g/mol |
| Half-life | Not documented | ~13 hours |
| Origin | The DURATION-1 trial compared two exenatide formulations over 30 weeks in 295 adults with type 2 diabetes. This entry adds a formulation-focused comparator to the GLP-1 library. | Developed by Novo Nordisk as an acylated analog of human GLP-1 and one of the earlier long-acting GLP-1 receptor agonists. It received first FDA approval in 2010. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Exenatide works
Its GLP-1 receptor activity provides the mechanistic context for studies of glucose regulation.
How Liraglutide works
Liraglutide is an analog of native GLP-1 sharing high sequence homology with the human hormone. It activates the GLP-1 receptor to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. A C16 palmitic fatty-acid chain attached via a glutamate linker promotes albumin binding and self-association, extending its duration relative to native GLP-1 and enabling once-daily dosing.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Exenatide
Liraglutide
What sets each apart
Exenatide
A randomized, open-label non-inferiority study; formulation and trial design matter when interpreting the results. Findings in this population do not establish effects in healthy people.
Liraglutide
Liraglutide is a once-daily GLP-1 agonist with a shorter half-life than the once-weekly semaglutide, reflecting its earlier-generation design.
Frequently asked questions
What is the evidence context for Exenatide?
A randomized, open-label non-inferiority study; formulation and trial design matter when interpreting the results. Findings in this population do not establish effects in healthy people.
Does this reference establish that a supplier product is equivalent?
No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.
What is liraglutide and how does it differ from weekly GLP-1 agonists?
Liraglutide is a GLP-1 receptor agonist with a single C16 fatty-acid acylation that provides albumin binding and a roughly 13-hour half-life. Because that half-life is much shorter than semaglutide's, it is administered once daily rather than weekly in the literature. It is an earlier-generation reference GLP-1 agonist studied in glucose and body-weight models.
What does liraglutide's ~13-hour half-life imply for research design?
The ~13-hour half-life means once-daily administration and a much faster approach to steady state (within a few days) compared with weekly agonists. Washout is correspondingly quick — on the order of a few days. This daily-dosing profile is the main pharmacokinetic contrast researchers cite versus semaglutide and tirzepatide.
How is liraglutide dose-escalated in the literature?
Published protocols escalate daily, commonly starting at 0.6 mg and stepping up weekly through 1.2, 1.8, 2.4, and up to 3.0 mg once daily, depending on the endpoint studied. Escalation is used to improve gastrointestinal tolerability. These are reference figures for research context only, not human dosing guidance.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.
Linked publications
Publications recorded on each compound's profile, including original studies and reviews. These are background sources for the separate compounds; listing them together does not establish a direct comparison, a combination study, or equivalent evidence. Read the study design and limitations before interpreting a finding.